In early 2013, Roche signed a $595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker got cold feet over the summer, and now Chiasma is picking up the pieces, raising cash in hopes of submitting its drug to regulators this year.
Rebounding from a disappointing IPO, Israel's NeuroDerm watched its shares more than double on promising results from a small study of its Parkinson's disease treatments.
Spark Therapeutics jumped into existence late in 2013 with a pipeline of gene therapy projects spawned by investigators at the Children's Hospital of Philadelphia and quickly followed up this year with a $73 million round, breakthrough drug status and a $280 million partnership with Pfizer. Now it's ending its freshman year by filing to go public.
Flex Pharma, founded by serial biotech entrepreneur Christoph Westphal, is lining up for an IPO less than a year after its launch, angling to raise $60 million to bankroll its work in muscle disorders.
Back in the summer of 2013, Celgene lined up with a group of stalwarts to pump $33 million into the struggling regenerative medicine company Tengion, which had two programs in early-stage development. Today, the biotech powerhouse was listed as a creditor on an international roster of R&D groups and support companies that are getting stiffed in a Chapter 7 filing.
Eight months after OncoGenex Pharmaceuticals and Teva acknowledged that their experimental cancer drug custirsen had flopped in a Phase III prostate cancer study, the big Israeli pharma company has executed a strategic retreat from their partnership. Teva is handing over $27 million to OncoGenex to complete the divorce and is walking away from a deal that included $60 million in upfront costs back in 2009.
Here's a perennial favorite among the top trends in the industry. About six years ago, most of Big Pharma got serious about one of its biggest problems: they were really, really bad at drug development.
The world of gene therapy--in which single-dose treatments correct debilitating defects--enjoyed something of a renaissance in 2014. Strong clinical results from leaders in the once-maligned field spurred renewed optimism, helping a new generation of startups secure millions in venture financing to develop their next-generation approaches to the field.
After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, a new class of cancer treatments has finally made its way onto the market, opening up what's expected to become a multibillion-dollar industry.
The billions of dollars raised on the market in IPOs and secondary offerings has been bankrolling an expanding amount of development work at companies around the world. For biotech, these are the days.
In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution.
Billions of dollars in new biotech investments are being made, R&D is being globalized more than ever before and new technologies and drug classes are moving fast through the clinic. FierceBiotech assesses what we believe are the 5 top trends to watch in the year ahead.
Two months after its self-imposed deadline, the FDA finally signed off on Novo Nordisk's first weight-loss therapy, a milestone for the company as it blueprints a future in obesity.
An upstart biotech based in Bermuda says that it has in-licensed an Alzheimer's drug from GlaxoSmithKline and plans to take it into Phase III studies next year.
Vanda Pharmaceuticals has come out at the other end of its dispute with former partner Novartis, getting back the rights to its schizophrenia drug and banking an equity investment from the Swiss drugmaker.
The J&J Innovation center in California has helped orchestrate a deal with San Diego-based Sevion Therapeutics to develop new antibodies for a Janssen affiliate, CNA Development.
The prostate cancer experts at Medivation are getting into the hot field of checkpoint inhibitors for cancer, agreeing to pay Israel's CureTech as much as $335 million for the full rights to a promising Phase II asset.
Embattled biotech Ariad Pharmaceuticals has signed a deal with Japan's Otsuka to trade the Asian rights to its top cancer drug in exchange for $77.5 million and the promise of more down the line.
Astellas has capped a string of new drug development deals by upping the ante on its pact with South San Francisco-based Cytokinetics. After handing over a $40 million upfront fee for their original 2013 deal, Astellas has come back with $75 million more in near-term financing and more than $600 million in milestones on the table.